HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)
British Journal of Clinical Pharmacology · 2026-07 · 92 (7) · 1957-1976
DOI: 10.1002/bcp.70559 ↗Kurz gefasst
Leitlinie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 19.04.2026. Verfasst von Lucy Galloway und 24 weiteren Autor:innen. Beteiligte Einrichtung: NHS South East Genomic Medicine Service, St George's University Hospitals NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Oxcarbazepine, Carbamazepine, Dibenzazepines, Anticonvulsants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity. The liver and other organ systems can also be affected. The HLA alleles, HLA‐B*15:02 , HLA‐B*15:11 and HLA‐A*31:01 , are known predisposing factors for these hypersensitivity reactions. Any treatment‐naïve patient, regardless of ancestry or indication for treatment, who is about to be prescribed carbamazepine, oxcarbazepine or eslicarbazepine, or has been on these drugs for less than 3 months, should undergo pharmacogenetic testing to identify all clinically relevant HLA alleles to reduce the risk of hypersensitivity reactions. Carbamazepine, oxcarbazepine and eslicarbazepine should be avoided in HLA‐B*15:02 ‐positive patients. These drugs should also be avoided in patients positive for HLA‐A*31:01 or HLA‐B*15:11 if an alternative is possible. Where it is not possible to use an alternative, treatment should only be commenced after careful consideration of the benefits and risks, with increased monitoring and advising patients on appropriate action to take if a skin rash occurs. Our guideline is compatible with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk–benefit profile, ensuring that therapy is optimised to maximise benefits whilst minimising potential harms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHS South East Genomic Medicine Service, St George's University Hospitals NHS Foundation Trust, London, UK.
- Faculty of Life Sciences & Medicine, King's College London, London, UK.
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool, Liverpool, UK.
- Department of Translational Medicine and Surgery, Section of Pharmacology, Università Cattolica del Sacro Cuore-Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
- Division of Psychiatry, University College London, London, UK.
- North London NHS Foundation Trust, London, UK.
ORCID-Profile: Lucy Galloway, Cinzia Dello Russo, Dyfrig A Hughes, Munir Pirmohamed
Zitieren
APA
Galloway, L., Dello Russo, C., Bass, N., Bramon, E., Cross, H., Curley, N., Curran, S., Davies, H., De Villiers, J., Evans, W., Frank, B., Groves, A., Hayward, J., Higham, J., Hughes, D. A., Kyaw, S. S., Marson, A. G., McLellan, A., Mensah, S., …, & Pirmohamed, M. (2026). HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology, 92(7), 1957-1976. https://doi.org/10.1002/bcp.70559
Vancouver
Galloway L, Dello Russo C, Bass N, Bramon E, Cross H, Curley N, et al. HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology. 2026;92(7):1957-1976. doi:10.1002/bcp.70559
BibTeX
@article{Galloway2026,
author = {Galloway, Lucy and Dello Russo, Cinzia and Bass, Nicholas and Bramon, Elvira and Cross, Helen and Curley, Natalie and Curran, Sarah and Davies, Helen and De Villiers, Jana and Evans, William and Frank, Bernhard and Groves, Alice and Hayward, Judith and Higham, Jon and Hughes, Dyfrig A and Kyaw, Shwe Sin and Marson, Anthony G and McLellan, Ailsa and Mensah, Seth and O'Neill, Francis and Sargison, Jane and Sisodiya, Sanjay M and Swan, Jill and Zakrewska, Joanna M and Pirmohamed, Munir},
title = {HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {7},
pages = {1957--1976},
doi = {10.1002/bcp.70559}
}
EUVIMED